If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in London. Directors from London Stock Exchange listed companies will present their latest plans regarding development and growth, you will have also have the opportunity to talk directly to the Directors and put forward your questions.
PrimaryBid - PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions. To date almost £37m has been sourced for issuers, via the platform.
Rockhopper Exploration (RKH) - Rockhopper is an AIM listed oil and gas company based in the UK with interests in the Falkland Islands and the Greater Mediterranean region. Rockhopper’s strategy is to build a well-funded, full-cycle, exploration led E&P company.
The Company is the leading acreage holder in the North Falkland Basin with independently audited 2C oil resources, net to Rockhopper, in excess of 250 mmbbl.
Through a series of acquisition and organic growth initiatives, Rockhopper has built a portfolio of production and exploration assets in the Greater Mediterranean which produced approximately 1,350 boepd during 2016 and is expected to generate material future exploration activity.
Valirx (VAL) - Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.
Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.
The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.
Who Should Attend
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Registration and coffee
Dave Mutton, COO - PrimaryBid
Stewart MacDonald, CFO - Rockhopper Exploration (RKH)